Jonathan Hepple

Jonathan Hepple has extensive work experience in the field of non-executive director roles. Jonathan began their career in 2009 as the Founder & Director of Rosetta Capital. In 2013, they became a Non-Executive Director for Clanotech AB, Axelar AB, and Novimmune. Jonathan then became a Non-Executive Director for Aprea AB in 2015. In 2020, they joined Nucleome Therapeutics as a Non-Executive Director and Oxford Science Enterprises as a Strategic Advisor. In 2021, they were appointed Non-Executive Director for Carrick Therapeutics and Mission Therapeutics.

Jonathan Hepple completed a PhD in Cancer Research and Protein Engineering at the University of Cambridge between 1993 and 1998. Prior to that, they studied Biology at the University of Oxford from 1989 to 1992.